Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection

REC-3964 is Recursion’s first new chemical entity developed using the RecursionOS. REC-3964 represents a novel, non-antibiotic approach with a unique mechanism of action that binds and blocks catalytic activity of the toxin’s innate glucosyltransferase in order to inhibit the toxin produced by C. diff. in the gastrointestinal tract. There are up to 175,000 cases of recurrent C. diff. each […]

Incroyable Jeff ! IriusRisk présente un outil basé sur l’IA capable de générer des modèles de menaces à partir d’images

La plateforme de modélisation des menaces lance « Jeff : Assistant IA », une première mondiale en termes de création de modèles de menaces à travers le langage et les images. Cette nouvelle fonctionnalité marque l’un des tout derniers développements de la percée d’IriusRisk dans le domaine de l’IA, initiative qui a contribué à générer une croissance de […]

Unbelievable Jeff! IriusRisk introduces an AI-powered tool which can generate threat models from images

The threat modeling platform launches ‘Jeff: AI Assistant’, a world first in terms of creating threat models through language and images. The new feature is the latest development in IriusRisk’s expansion into AI, a move which helped to deliver more than 50% Annual Recurring Revenue (ARR) growth last year. ATLANTA, Oct. 22, 2024 (GLOBE NEWSWIRE) […]

Quantexa Recognized as Category Leader in the RiskTech Quadrant® for KYC Solutions

Quantexa earned a top ranking in the RiskTech100® 2025 Report, highlighting its strength and innovation in the expanding risk technology and compliance market LONDON, Oct. 22, 2024 (GLOBE NEWSWIRE) — Quantexa, a leading provider of Decision Intelligence solutions for public and private sectors, today announced it has received recognition in two Chartis Research reports. Quantexa […]